electroCore,

electroCore, EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of electroCore, (ECOR) as of Oct 18, 2026 is -13.67 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -12.16 M USD — a change of 12.41% (lower).

EBITDA

-13.67 MUSD

YoY

12.41%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of electroCore, is 2025 -13.67 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of electroCore, was 2024 -12.16 M USD. It decreases by 12.41% lower compared to the previous year.

The electroCore, EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-54.55 M USD
Jan 1, 2019
-46.09 M USD
Jan 1, 2020
-24.75 M USD
Jan 1, 2021
-20.04 M USD
Jan 1, 2022
-22.87 M USD
Jan 1, 2023
-18.81 M USD
Jan 1, 2024
-12.16 M USD
Jan 1, 2025
-13.67 M USD
The electroCore, EBITDA history
YEAREBITDAYoY
-13.67 MUSD+12.41%
-12.16 MUSD-35.33%
-18.81 MUSD-17.79%
-22.87 MUSD+14.12%
-20.04 MUSD-19.01%
-24.75 MUSD-46.30%
-46.09 MUSD-15.52%
-54.55 MUSD+88.73%
-28.91 MUSD+92.57%
-15.01 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of electroCore, is -13.67 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of electroCore, changed from -12.16 M USD to -13.67 M USD, representing a 12.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) electroCore, since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s electroCore, historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — electroCore,

All Key Metrics — electroCore,